These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27075627)

  • 21. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
    Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
    [No Abstract]   [Full Text] [Related]  

  • 22. Serine/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer.
    Zhu Z; Xiang Q; Li S; Chen C; Shi J
    Biochem Pharmacol; 2024 Jul; 225():116268. PubMed ID: 38723720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
    Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
    Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
    Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
    Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitric Oxide-Releasing Drug Glyceryl Trinitrate Targets JAK2/STAT3 Signaling, Migration and Invasion of Triple-Negative Breast Cancer Cells.
    Bouaouiche S; Ghione S; Sghaier R; Burgy O; Racoeur C; Derangère V; Bettaieb A; Plenchette S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
    BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
    Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM
    Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
    Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8
    Kalimutho M; Sinha D; Mittal D; Srihari S; Nanayakkara D; Shafique S; Raninga P; Nag P; Parsons K; Khanna KK
    J Exp Clin Cancer Res; 2019 Feb; 38(1):85. PubMed ID: 30777101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting a cell state common to triple-negative breast cancers.
    Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
    Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quercetin exerts anti-tumor immune mechanism by regulating IL-6/JAK2/STAT3 signaling pathway to deplete Treg cells.
    Liao Y; Xie X; Zhang C; Zhong H; Shan L; Yu P; Xu L
    Toxicon; 2024 May; 243():107747. PubMed ID: 38714236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
    Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
    Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.
    Balanis N; Carlin CR
    Mol Cell Endocrinol; 2017 Aug; 451():24-30. PubMed ID: 28088463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.
    Van Roosbroeck K; Ferreiro JF; Tousseyn T; van der Krogt JA; Michaux L; Pienkowska-Grela B; Theate I; De Paepe P; Dierickx D; Doyen C; Put N; Cools J; Vandenberghe P; Wlodarska I
    Genes Chromosomes Cancer; 2016 May; 55(5):428-41. PubMed ID: 26850007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
    Stover DG; Coloff JL; Barry WT; Brugge JS; Winer EP; Selfors LM
    Clin Cancer Res; 2016 Dec; 22(24):6039-6050. PubMed ID: 27330058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).
    Wein L; Loi S
    Breast; 2017 Aug; 34 Suppl 1():S27-S30. PubMed ID: 28668293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.